巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    MDxHealth SA

    MDXH
    7.330
    0.000
    0.00%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・MDxHealth SA - 延遲價格・最後更新於 29/09 1:30
    最高位
    --
    最低位
    --
    開市價
    --
    前收市價
    7.330
    成交量(千)
    --
    成交額(百萬)
    --
    買入
    6.410
    賣出
    6.570
    每手股數
    --
    市值(百萬)
    119.39
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    13.170 - 6.000
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    MDxHealth SA
    證券代碼
    MDXH.US
    所屬板塊
    Diagnostics & Research
    公司業務
    MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.
    發行量
    15596922
    公司總部
    Rue d’Abhooz, 31, Cap Business Center, Herstal
    公司網址
    https://www.mdxhealth.com
    公司電郵
    ir@oncomethylome.com
    公司電話
    +32 43642070
    暫無內容

    關於

    MDxHealth SA(MDXH.US)所屬的行業板塊為Diagnostics & Research。
    MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.
    詳細公司背景可參考: https://www.mdxhealth.com